Patients in intensive care units (ICUs) face a high risk of morbidity and mortality not only from their primary critical illnesses but also from secondary complications such as nosocomial infections. Pneumonia is the second most common hospital-acquired infection in critically ill patients, affecting approximately 27% of this population. Mechanical ventilation, a vital life-saving intervention, is a major risk factor for hospital-acquired pneumonia due to factors such as aspiration, impaired consciousness, frequent patient handling, and pre-existing lung conditions. Ventilator-associated pneumonia (VAP) typically develops within 48 to 96 hours after initiation of mechanical ventilation, with reported incidence rates ranging from 9% to 67% and mortality rates between 13% and 94%. VAP contributes to prolonged hospitalization, increased healthcare costs, and elevated patient morbidity and mortality. Evidence-based interventions, including strict infection control practices, ventilator care bundles, and early mobilization, have been shown to reduce the risk and incidence of VAP. Systematic reviews indicate that 10% to 20% of patients receiving mechanical ventilation for more than 48 hours develop VAP. Understanding the epidemiology, risk factors, and preventive strategies of VAP is essential to improving patient outcomes in the ICU setting.